8-K: Immunocore Holdings Files Prospectus Supplement for Resale of American Depositary Shares
Prospectus Supplement Filing
Immunocore Holdings has filed a prospectus supplement for the resale of up to 1,220,063 American Depositary Shares by a selling shareholder.
Summary
- Immunocore Holdings plc filed a prospectus supplement on April 5, 2024, related to the resale of up to 1,220,063 American Depositary Shares (ADS).
- These ADSs represent the right to receive ordinary shares, each with a nominal value of 0.002 per share.
- The resale is by a selling shareholder, as detailed in the prospectus supplement.
- The company also filed a legal opinion from Cooley (UK) LLP regarding the validity of the shares being registered.
Sentiment
Score: 7
Explanation: The document is a routine filing related to a share resale, which is neither particularly positive nor negative. The legal opinion adds a layer of assurance, resulting in a slightly positive sentiment.
Positives
- The legal opinion from Cooley (UK) LLP provides assurance regarding the validity of the shares being registered.
Industry Context
This announcement is a standard procedure for companies that have previously issued shares and are now facilitating the resale of those shares by existing shareholders. It is common for companies to file prospectus supplements and legal opinions in such cases.
Comparison to Industry Standards
- The filing of a prospectus supplement for the resale of shares is a common practice among publicly traded companies, particularly those that have previously conducted private placements.
- The legal opinion provided by Cooley (UK) LLP is a standard requirement to ensure the validity of the shares being registered for resale.
- Companies like Immunocore, which have raised capital through private placements, often need to facilitate the resale of these shares by investors, and this filing is a typical step in that process.
Stakeholder Impact
- The resale of shares may provide liquidity for the selling shareholder.
- The filing ensures compliance with securities regulations, which is beneficial for all shareholders.
Key Dates
| Date | Description |
|---|---|
| January 7, 2021 | Date of the certificate of incorporation of the Company. |
| February 1, 2021 | Date of the certificate of incorporation on re-registration of the Company as a public company. |
| February 3, 2021 | Date of the general meeting of the Company where resolutions were passed to authorize the Directors to allot shares. |
| February 9, 2021 | Date the articles of association of the Company were adopted. |
| November 8, 2021 | Effective date of the financing and pricing committee of the Board. |
| April 29, 2022 | Date of the Board meeting where Siddharth Kaul was appointed to the Committee. |
| July 15, 2022 | Date of the Registration Rights Agreement and the Securities Purchase Agreement between the Company and certain investors. |
| July 11, 2022 | Date of the Committee meeting where the allotment and issue of the Private Placement Non-Voting Ordinary Shares was authorized. |
| March 21, 2024 | Date the Company filed the registration statement on Form S-3ASR with the SEC. |
| April 5, 2024 | Date of the prospectus supplement filing and the legal opinion from Cooley (UK) LLP. |
Keywords
American Depositary Shares, ADS, Immunocore Holdings, Prospectus Supplement, Resale, Ordinary Shares, Legal Opinion, Cooley (UK) LLP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.